Trials / Completed
CompletedNCT00266877
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 172 (actual)
- Sponsor
- Puma Biotechnology, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn whether HKI-272 is safe and effective in treating non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HKI-272 | 320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability. |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2005-12-19
- Last updated
- 2018-04-13
- Results posted
- 2018-04-13
Locations
19 sites across 5 countries: United States, France, Hungary, Poland, Spain
Source: ClinicalTrials.gov record NCT00266877. Inclusion in this directory is not an endorsement.